治疗方式对局部晚期胃癌的影响 - - 现实世界数据
1Adıyaman Training and Research Hospital Medical Oncology Department, Adiyaman 02040, Turkey.
Current oncology (Toronto, Ont.)
|August 27, 2025
概括
在局部发达的胃癌中,辅助化疗 (ACT) 的生存时间比新辅助化疗 (NACT) 长. 然而,患者选择和基线差异,而不是化疗时间,可能解释了这一点,需要进一步的随机试验.
科学领域:
- 癌症学
- 胃肠道瘤学
- 临床癌症研究
背景情况:
- 在局部晚期胃癌 (LAGC) 中,化疗的最佳时间是有争议的.
- 将辅助化疗 (ACT) 与新辅助化疗 (NACT) 进行比较对于治疗策略至关重要.
研究的目的:
- 在LAGC患者中比较ACT和NACT的生存结果 (PFS,OS).
- 在现实环境中确定影响生存的临床病理因素.
主要方法:
- 对103名LAGC患者 (2014 - 2024年) 的回顾性分析.
- 分类为ACT (n=56) 和NACT (n=47) 组.
- 卡普兰-梅尔和考克斯回归用于生存和预后因素评估.
主要成果:
- NACT组:较年轻,较近端的瘤. 中位数OS:ACT 48. 7个月与NACT 17. 7个月 (p=0. 048). 中位数PFS:ACT没有达到与NACT15.6个月 (p=0.008).
- 阴性手术边缘和年轻的年龄是生存的独立预后因素.
- 由于病情进展或不耐受,21%的NACT患者没有接受手术.
结论:
- 观察到的生存差异可能是由于患者选择和基线不平衡,而不是化疗序列.
- 需要仔细选择患者进行NACT.
- 强调有必要进行前性随机研究,以确定LAGC的最佳化疗序列.
更多相关视频
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
848
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
